2024
Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes
Kiwan A, Kewan T, Xu M, Siddon A, Girardi M, Sethi T, Foss F. Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes. Blood 2024, 144: 4440-4440. DOI: 10.1182/blood-2024-205144.Peer-Reviewed Original ResearchGene copy number alterationsAssociated with poor OSAbsolute lymphocyte countFluorescence in situ hybridization panelAssociated with worse OSCirculating tumor cellsFluorescence in situ hybridizationOverall survivalCopy number alterationsT cell receptorPoor OSSurvival outcomesTumor cellsMedian OSCox proportional hazardsBlood involvementATM deletionArid1a deletionT cellsElevated absolute lymphocyte countMedian absolute lymphocyte countAssociated with better OSMedian age of patientsMultivariate CPH modelZEB1 deletionSpatial Multiomics Profiling of Angioimmunoblastic T-Cell Lymphoma
Enninful A, Foss F, Fan R, Xu M. Spatial Multiomics Profiling of Angioimmunoblastic T-Cell Lymphoma. Blood 2024, 144: 1585-1585. DOI: 10.1182/blood-2024-211129.Peer-Reviewed Original ResearchAngioimmunoblastic T-cell lymphomaT follicular helper cellsT-cell lymphomaFollicular dendritic cellsHigh endothelial venulesT cellsTumor cellsTumor microenvironmentB cellsImmune surveillanceMultiplex immunofluorescenceCD21+ follicular dendritic cellsTumor evasion of immune surveillanceNon-neoplastic T cellsEvasion of immune surveillanceEBV-positive B cellsGene activity scoreTissue blocksActivity of tumor cellsReactive B cellsExpression of LMP1Positive B cellsComplex tumor microenvironmentT cell zonesLymph node sampling
2006
Immunomodulatory Effects of Rexinoids
Foss F. Immunomodulatory Effects of Rexinoids. Seminars In Oncology 2006, 33: 21-25. PMID: 16516672, DOI: 10.1053/j.seminoncol.2005.12.019.Peer-Reviewed Original ResearchConceptsImmunomodulatory effectsCutaneous T-cell lymphomaReceptor-targeted therapyImproved clinical outcomesT-cell lymphomaPractical clinical approachExtracorporeal photophoresisClinical outcomesDenileukin diftitoxTherapy optionsHematologic malignanciesClinical activityPharmacotherapeutic agentsLymphoid malignanciesClinical approachTumor cellsRexinoidsMalignancyTreatmentDiftitoxLymphomaTherapy
2002
Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene
Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM. Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. Leukemia Research 2002, 26: 1077-1083. PMID: 12443879, DOI: 10.1016/s0145-2126(02)00059-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArginineButyratesCell SurvivalCyclic AMPDiphtheria ToxinDose-Response Relationship, DrugDrug SynergismHumansInterleukin-2Interleukin-2 Receptor beta SubunitLeukemiaLymphomaReceptors, InterleukinReceptors, Interleukin-2Recombinant Fusion ProteinsResponse ElementsSecond Messenger SystemsUp-RegulationConceptsCutaneous T-cell lymphomaIL-2R expressionNon-Hodgkin lymphomaArginine butyrateIL-2RLow affinity IL-2RHistone deacetylaseDirect growth-inhibitory effectB-cell non-Hodgkin lymphomaHigh-affinity IL-2 receptorLeukemia cellsCAMP response elementT-cell lymphomaIL-2 receptorNative diphtheria toxinGrowth inhibitory effectsClinical trialsP75 subunitAchievable concentrationsResponse rateVitro dataDAB389IL-2Interleukin-2 geneTumor cellsLymphoma cellsImmunologic mechanisms of antitumor activity
Foss FM. Immunologic mechanisms of antitumor activity. Seminars In Oncology 2002, 29: 5-11. PMID: 12068382, DOI: 10.1053/sonc.2002.33076.Peer-Reviewed Original ResearchConceptsAntigen-presenting cellsCytotoxic T lymphocytesEffector cellsCostimulatory moleculesT lymphocytesImmune responseTumor antigensImmune effectorsTumor-specific cytotoxic T lymphocytesTumor cellsMHC complexesEffector cell expansionInadequate immune responseImmune effector cellsHost immune surveillanceAntigen class ICostimulatory adhesion moleculesTumor-associated peptidesT cell receptorOverall immunosuppressionCytokine therapyImmunologic mechanismsAdvanced cancerAntitumor responseTumor escape